CENTOCOR INC

Centocor Inc. operates as a leader in diagnostic reagents and biologics rooted in the SIC realm of In Vitro & In Vivo Diagnostic Substances, offering monoclonal antibody kits, immunoassay platforms, and specialized contract testing services that support hospital labs, biopharma researchers, and public health agencies needing reliable measurement of biomarkers. The company designs and manufactures both reagent-grade antibodies and integrated testing systems, aligning with the post-1999 surge in personalized medicine diagnostics, while its customer base spans clinical labs, academic institutions, and pharmaceutical partners seeking assay validation and custom antibody development. Amid evolving federal oversight over biologics and diagnostics, Centocor faces material risks from FDA premarket review timelines, manufacturing compliance, and reimbursement pressure that could impact long-term production capacity and revenue stability. The latest publicly filed report, the Form 10-Q for the quarter ended August 1999, outlines these operational dynamics and regulatory touchpoints, and for deeper context on this ongoing narrative, view live SEC filings on Earnings Feed.

Source: Earnings Feed research · last updated 11/24/2025